Journal of cancer science and clinical therapeutics最新文献

筛选
英文 中文
Survival Benefits Associated with Surgery in Patients with Metastatic Breast Cancer by Breast Cancer Subtype 乳腺癌亚型转移性乳腺癌患者手术相关的生存获益
Journal of cancer science and clinical therapeutics Pub Date : 2021-01-01 DOI: 10.26502/jcsct.5079127
H.S. Han, T. -, Jyh‐cherng Yu, M. Golshan, Huan-Ming Hsu, C. Chu, Z. Hong, C. Fu, Y. Chou, M. Dai, G. Liao
{"title":"Survival Benefits Associated with Surgery in Patients with Metastatic Breast Cancer by Breast Cancer Subtype","authors":"H.S. Han, T. -, Jyh‐cherng Yu, M. Golshan, Huan-Ming Hsu, C. Chu, Z. Hong, C. Fu, Y. Chou, M. Dai, G. Liao","doi":"10.26502/jcsct.5079127","DOIUrl":"https://doi.org/10.26502/jcsct.5079127","url":null,"abstract":"Background: Two randomized trials have examined the role of local therapy on survival in the stage IV setting of breast cancer, largely suggesting no benefit. However, the effect of surgery for stage IV disease amongst various breast cancer subtypes is not well characterized. In this study, we aimed to evaluate the survival benefit of surgery in patients with stage IV breast cancer based on molecular subtype. J Cancer Sci Clin Ther 2021; 5 (3): 414-425 DOI: 10.26502/jcsct.5079127 Journal of Cancer Science and Clinical Therapeutics 415 Methods: Using an institutional database, we extracted 255 women with a clinicopathologic confirmed diagnosis of stage IV breast cancer who were treated between January 2006 and October 2016. We collected patient data including age, clinical T stage, clinical N stage, histological grade, estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, and the use of radiotherapy, chemotherapy, targeted therapy and/or endocrine therapy. Correlates of overall survival (OS) and breast cancer-specific survival (BCSS) in the surgical and non-surgical groups were identified on multivariate analysis. Results: The median overall survival in the surgical group and the non-surgical group was 30.3 months and 20.7 months, respectively. There were significant differences between the two groups according to subtype in the distribution of OS and BCSS (P <0.001). On multivariate analysis for the OS and BCSS, using non-surgical group as a reference, there were significant improvement for the luminal B subtype (P=0.010). Conclusion: This study suggest that surgery of the primary breast tumor may have a positive impact on OS and BCSS in patients with stage IV breast cancer, especially in the luminal B subtype.","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69348050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Analytical Anisotropic Algorithm Calculation in Total Body Irradiation: A Comparison with Monte Carlo Calculation and Dosimetry 全身照射的解析各向异性算法计算:与蒙特卡罗计算和剂量法的比较
Journal of cancer science and clinical therapeutics Pub Date : 2021-01-01 DOI: 10.26502/jcsct.5079136
Saikkonen A, Ojala J, Keyrilainen J
{"title":"Analytical Anisotropic Algorithm Calculation in Total Body Irradiation: A Comparison with Monte Carlo Calculation and Dosimetry","authors":"Saikkonen A, Ojala J, Keyrilainen J","doi":"10.26502/jcsct.5079136","DOIUrl":"https://doi.org/10.26502/jcsct.5079136","url":null,"abstract":"Purpose: This study aimed to investigate the feasibility and accuracy of an analytical anisotropic algorithm calculation of the Varian Eclipse treatment planning system in the TBI treatment planning at an extended source-to-surface distance of 400 cm. Materials and Methods: The TBI treatment was planned with the Varian Eclipse TPS using the AAA for the dose calculation. Monte Carlo calculations were performed using the EGSnrc code package. Percentage depth dose curves, central axis dose profiles and absolute doses of the 6 MV photon beams from the Varian TrueBeam linear accelerator were measured at an extended SSD of 400 cm in water, solid water and anthropomorphic phantoms. Results: Calculated and measured PDD curves were in good agreement at the depths of 30.0 cm or less. Calculated J Cancer Sci Clin Ther 2021; 5 (4): 532-547 DOI: 10.26502/jcsct.5079136 Journal of Cancer Science and Clinical Therapeutics 533 and measured central axis dose profiles were clinically acceptable, observing the largest uncertainties close the field edges. Absolute dose measurements in water phantoms showed that the MC and AAA calculations overestimated doses by up to 2.2 % and 1.8 %, respectively. In the anthropomorphic phantom, the difference between measured and calculated mean doses in the whole body volume was 1.0 % and 6.2 % for MC and AAA, respectively. In the AAA calculation, the largest observed difference was 8.3 % in the head. Conclusions: The Eclipse’s AAA calculation can be safely used for the TBI treatment planning at the extended SSD of 400 cm. However, in order to achieve a higher level of accuracy in the TBI planning, one must carefully validate the TPS at extended SSDs.","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69348163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Profile of Tissue Selenium Concentration In A Cohort Of Nigerian Men With Prostate Cancer 尼日利亚前列腺癌男性队列组织硒浓度分析
Journal of cancer science and clinical therapeutics Pub Date : 2021-01-01 DOI: 10.26502/jcsct.5079140
Igbokwe Mc, Badmus Ta, Salako Aa, Obiajunwa Ei, O. O., Igbokwe Ca, D. ra
{"title":"Profile of Tissue Selenium Concentration In A Cohort Of Nigerian Men With Prostate Cancer","authors":"Igbokwe Mc, Badmus Ta, Salako Aa, Obiajunwa Ei, O. O., Igbokwe Ca, D. ra","doi":"10.26502/jcsct.5079140","DOIUrl":"https://doi.org/10.26502/jcsct.5079140","url":null,"abstract":"","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"59 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69348208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identifying the Mutational Profile of ABCB5 Upregulation in Colorectal Cancer: A Comprehensive Database Analysis 确定结直肠癌中ABCB5上调的突变谱:一个全面的数据库分析
Journal of cancer science and clinical therapeutics Pub Date : 2021-01-01 DOI: 10.26502/jcsct.5079123
R. Sexton, K. Danasekaran, H. Khan, H. Uddin, M. N. Al-Hallak, Y. Landesman, T. Kashyap, Yiwei Li, A. Aboukameel, A. Azmi
{"title":"Identifying the Mutational Profile of ABCB5 Upregulation in Colorectal Cancer: A Comprehensive Database Analysis","authors":"R. Sexton, K. Danasekaran, H. Khan, H. Uddin, M. N. Al-Hallak, Y. Landesman, T. Kashyap, Yiwei Li, A. Aboukameel, A. Azmi","doi":"10.26502/jcsct.5079123","DOIUrl":"https://doi.org/10.26502/jcsct.5079123","url":null,"abstract":"Colorectal cancer (CRC) is a leading cause of cancer related deaths worldwide and the third leading cause of cancer related deaths in the United States with a 5-year survival rate of 63%. Depending on the stage of disease, there are differing rates of overall survival: Stage I (90%) vs. Stage IV (14%). There is a clear discrepancy between early and late stage disease due to a variety of factors including acquired genetic and tumor mutations and lack of initial symptoms leading to late stage detection. It is clear that further understanding into the mechanisms of CRC need to be explored in depth to improve overall survival rates. ATP binding cassette subfamily B member 5 (ABCB5) has been found to be pathogenic in a variety of diseases including melanoma and colorectal cancer but there has been few studies looking at the cellular consequences of ABCB5 upregulation in CRC cells. Using publicly accessible databases, we explored ABCB5 positivity in CRC cells and found novel interactions with 64 differentially expressed genes involved in cellular processes like modulation of inflammation, (XCL1, TNFSF4), enhanced cell signaling via interaction with serine protease inhibitors (SERPINB4, WFDC6) and downregulation of anti-apoptotic proteins (SPIN2A). Although ABCB5 upregulation is not currently targetable with pre-clinical compounds, our analysis revealed the genetic effects induced by ABCB5 upregulation are targetable, including evidence of sensitivity to the XPO1 inhibitor XPOVIO (selinexor). It is clear further pre-clinical investigation is needed to validate these findings.","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69367550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Experience using Osimertinib in Patients with Recurrent Malignant Gliomas Containing EGFR Alterations. 奥西美替尼治疗EGFR改变的复发性恶性胶质瘤的临床经验。
Journal of cancer science and clinical therapeutics Pub Date : 2021-01-01 Epub Date: 2021-04-29 DOI: 10.26502/jcsct.5079114
Marin Abousaud, Naqeeb M Faroqui, Glenn Lesser, Roy E Strowd, Shakti H Ramkissoon, Madan Kwatra, Kristin S Houston, Fang-Chi Hsu, Annette Carter, Robin Petro, Alisha T DeTroye
{"title":"Clinical Experience using Osimertinib in Patients with Recurrent Malignant Gliomas Containing <i>EGFR</i> Alterations.","authors":"Marin Abousaud, Naqeeb M Faroqui, Glenn Lesser, Roy E Strowd, Shakti H Ramkissoon, Madan Kwatra, Kristin S Houston, Fang-Chi Hsu, Annette Carter, Robin Petro, Alisha T DeTroye","doi":"10.26502/jcsct.5079114","DOIUrl":"10.26502/jcsct.5079114","url":null,"abstract":"<p><strong>Background: </strong><i>EGFR</i> alterations are commonly observed in malignant gliomas (MG). Osimertinib, an irreversible EGFR-tyrosine kinase inhibitor, effectively penetrates the blood brain barrier and achieves therapeutic concentrations in brain tissue.</p><p><strong>Materials and methods: </strong>This retrospective chart review identified six patients with recurrent MG and <i>EGFR</i> alterations who received osimertinib.</p><p><strong>Results: </strong>Four patients were assessed for response. One patient had a partial response, two patients achieved stable disease and one was refractory. One patient with an <i>EGFR vIII</i> rearrangement remained on treatment for 236 days and a second patient with an <i>EGFR vIII</i> mutation remained on treatment for 294 days and continued on treatment at the time of analysis. Thrombocytopenia occurred in two patients, one patient developed grade 1 diarrhea and pneumonia, and another patient developed grade 1 mucositis.</p><p><strong>Conclusion: </strong>Osimertinib had a tolerable safety profile in this heavily pretreated brain tumor population. Osimertinib may benefit select patients with recurrent MG containing <i>EGFR</i> alterations.</p>","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"5 2","pages":"210-220"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9121798/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9174799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epileptogenic Temporal lobe Intrinsic Epidermoid Tumor: A Rare Case Report and Review of the Literature 癫痫致颞叶内生性表皮样瘤1例报告及文献复习
Journal of cancer science and clinical therapeutics Pub Date : 2021-01-01 DOI: 10.26502/jcsct.5079124
Mohammad Sujan Sharif, Tarikul Islam KM, Abdur Rahman, Abu Bakar Siddik, Masum Rahman
{"title":"Epileptogenic Temporal lobe Intrinsic Epidermoid Tumor: A Rare Case Report and Review of the Literature","authors":"Mohammad Sujan Sharif, Tarikul Islam KM, Abdur Rahman, Abu Bakar Siddik, Masum Rahman","doi":"10.26502/jcsct.5079124","DOIUrl":"https://doi.org/10.26502/jcsct.5079124","url":null,"abstract":"Intracerebral epidermoid cysts are uncommon, accounting for only around 1.5 percent of intracranial tumors. Among these, Temporal lobe intracerebral epidermoid tumors are exceedingly rare. The great majority of these slow-growing tumors are asymptomatic, whereas few exhibit overt symptomatologies. We report a case of epidermoid tumors in a unique location, presented as a secondary complex partial seizure. A forty-year-old female presented with multiple episodes of convulsions followed by loss of consciousness for nine months, increasing in frequency over the last two months. MRI of the brain without contrast showed a well-circumscribed right temporal lobe mass, appearing hypointense on the T1 and hyperintense on the T2 sequence. In addition to our experience and review of existing literature demonstrate gross total resection of these lesions confers control of localization-related epilepsy.","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69367557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development and Management of Massive Subcutaneous Metastases with Unusual Clinical Course from Uterine Leiomyosarcoma 子宫平滑肌肉瘤伴异常病程的大量皮下转移的发展与处理
Journal of cancer science and clinical therapeutics Pub Date : 2021-01-01 DOI: 10.26502/jcsct.5079131
Filippin Dm, Nuvola G, Nannini M, S. M, Cammelli S, De Paolis M, Perrone Am, De Iaco P, De Leo A, A. A., Pan Ma
{"title":"Development and Management of Massive Subcutaneous Metastases with Unusual Clinical Course from Uterine Leiomyosarcoma","authors":"Filippin Dm, Nuvola G, Nannini M, S. M, Cammelli S, De Paolis M, Perrone Am, De Iaco P, De Leo A, A. A., Pan Ma","doi":"10.26502/jcsct.5079131","DOIUrl":"https://doi.org/10.26502/jcsct.5079131","url":null,"abstract":"Uterine leiomyosarcoma (U-LMS) is the most common histotype among all primary uterine sarcomas. The lung, peritoneum, pelvic or para-aortic lymph nodes, bone and liver are the most common metastatic sites involved. However, some case series of atypical sites of metastasis such as heart, brain and different endocrine glands have J Cancer Sci Clin Ther 2021; 5 (4): 459-467 DOI: 10.26502/jcsct.5079131 Journal of Cancer Science and Clinical Therapeutics 460 been described. Here we report the clinical presentation and therapeutic management of two patients affected by ULMS with a very atypical behavior, characterized by soft tissue metastases with an impressive and massive enlargement during chemotherapy despite a good control of the other sites of disease.","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69348090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stress-Induced Accumulation of HnRNP K into Stress Granules. 应力诱导的HnRNP - K在应力颗粒中的积累
Journal of cancer science and clinical therapeutics Pub Date : 2021-01-01 Epub Date: 2021-10-15 DOI: 10.26502/jcsct.5079129
Jayoung Kim, Austin Yeon, Woong-Ki Kim, Khae-Hawn Kim, Takbum Ohn
{"title":"Stress-Induced Accumulation of HnRNP K into Stress Granules.","authors":"Jayoung Kim, Austin Yeon, Woong-Ki Kim, Khae-Hawn Kim, Takbum Ohn","doi":"10.26502/jcsct.5079129","DOIUrl":"10.26502/jcsct.5079129","url":null,"abstract":"<p><p>Stress granules (SGs) are cytoplasmic aggregates to reprogram gene expression in response to cellular stimulus. Here, we show that while SGs are being assembled in response to clotrimazole, an antifungal medication heterogeneous nuclear ribonucleoprotein (hnRNP) K, an RNA-binding protein that mediates translational silencing of mRNAs, is rapidly accumulated in SGs in U-2OS osteosarcoma cells. Forced expression of hnRNP K induces resistance to clotrimazole-induced apoptosis. Erk/MAPK is transiently activated in response to clotrimazole, and pharmacological suppression of the Erk/MAPK pathway sensitizes the cells to apoptosis. Inhibition of the Erk/MAPK pathway promotes the assembly of SGs. These results suggest that dynamic cytoplasmic formation of SGs and hnRNP K relocation to SGs may be defensive mechanisms against clotrimazole-induced apoptosis in U-2OS osteosarcoma cells.</p>","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"5 1","pages":"434-447"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8955021/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49149480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Role of Radiation Therapy in Recurrent Ovarian Cancer 放射治疗在复发性卵巢癌中的作用
Journal of cancer science and clinical therapeutics Pub Date : 2021-01-01 DOI: 10.26502/jcsct.5079143
Yuichiro Hotta, Tamina Kino, H. Shigeta
{"title":"The Role of Radiation Therapy in Recurrent Ovarian Cancer","authors":"Yuichiro Hotta, Tamina Kino, H. Shigeta","doi":"10.26502/jcsct.5079143","DOIUrl":"https://doi.org/10.26502/jcsct.5079143","url":null,"abstract":"Recent remarkable technological advances in radiation therapy made the way for stereotactic body RT (SBRT), which can be used for oligometastatic tumors anywhere in the body. Oligometastases from gynecological malignancies have been considered as one of the most promising candidate for SBRT. It is suggested that SBRT was associated with high rates of local control, impressive survival, and minimal toxicity in ovarian cancer. It is also suggested that SBRT serves to destroy chemoresistant tumor clones, and help stimulate innate immune response or expose tumor neoantigens, and can be used in women who have had prior radiotherapy. Among the ovarian cancers, clear cell cancer might be a good candidate for radiation therapy because it is less sensitive to standard platinum-based chemotherapy. A patient was reported who had recurrent ovarian clear cell cancer and had been free from disease more than ten years after the discontinuation of proton beam therapy. Proton beam therapy provides superior dose distributions and a dosimetric advantages over photon beam therapy. Therefore, radiation therapy is considered to be an effective and safe option for oligometastatic ovarian cancer patients. Proton beam therapy is a good potential option for chemotherapy-resistant, localized, recurrent ovarian cancer including clear cell cancer. J Cancer Sci Clin Ther 2022; 6 (1): 25-30 DOI: 10.26502/jcsct.5079143 Journal of Cancer Science and Clinical Therapeutics 26","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69348225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Phase I dose escalation trial using Intensity-Modulated Radiotherapy with simultaneous integrated boost in Pelvic Chemoradiotherapy for Metastatic Rectal Cancer 一项I期剂量递增试验,使用调强放疗同时综合增强盆腔放化疗治疗转移性直肠癌
Journal of cancer science and clinical therapeutics Pub Date : 2020-12-16 DOI: 10.21203/rs.3.rs-127929/v1
T. Lizée, V. Seegers, J. Blanchecotte, E. Rio, O. Capitain, V. Guérin-Meyer, F. Legouté, D. Autret, M. Mahé, A. Paumier
{"title":"A Phase I dose escalation trial using Intensity-Modulated Radiotherapy with simultaneous integrated boost in Pelvic Chemoradiotherapy for Metastatic Rectal Cancer","authors":"T. Lizée, V. Seegers, J. Blanchecotte, E. Rio, O. Capitain, V. Guérin-Meyer, F. Legouté, D. Autret, M. Mahé, A. Paumier","doi":"10.21203/rs.3.rs-127929/v1","DOIUrl":"https://doi.org/10.21203/rs.3.rs-127929/v1","url":null,"abstract":"\u0000 BackgroundIn unresectable metastatic rectal cancers, the surgery of the primitive tumor remains highly debated. Chemoradiotherapy (CRT) of the primitive could allow sufficient local control in order to avoid major and sometimes mutilating surgery. Dose escalation during CRT could increase this local control. The aim of this study was to evaluate the feasibility and tolerance of a CRT with radiation dose escalation delivered in intensity modulated radiotherapy (IMRT) with simultaneous integrated boost (SIB), in metastatic low and middle rectal cancers.MethodsThis multicenter phase I study included six patients treated for unresectable synchronous metastatic low and middle rectal adenocarcinoma in two dose levels. Radiotherapy was delivered using IMRT with SIB. The dose escalation was 52.5 Gy (level 1) and 56.25 Gy (level 2) in the primary tumor, in 25 fractions of 2.1 Gy and 2.25 Gy, respectively. High-risk clinical target volume (CTV) and low-risk CTV received respectively 50 Gy and 45 Gy in 25 fractions in the two levels. Concomitant chemotherapy was oral capecitabine and CRT was performed after four cycles of mFOLOX6 chemotherapy. The dose-limiting toxicity (DLT) was defined by a toxicity requiring the interruption of radiotherapy for more than five consecutive fractions.ResultsAll six patients received the full course of treatment at scheduled doses. No patients had acute toxicity requiring interruption of radiotherapy therefore no DLT has been reported. No patients had acute toxicity ≥ 3. Concerning late toxicity, three patients experienced grade 3. After CRT, four patients had a partial response and one patient had a complete clinical response. Two patients were considered in local progression at 9.4 months and 20.4 months of inclusion.ConclusionsDose escalation at 56.25 Gy in the tumor lesion was possible with good acute tolerance. It needs to be evaluated in a larger study. It could allow sufficient local control in order to avoid mutilating surgery in these metastatic patients.Trial registrationNCT03634202. Registered 16 August 2018 – retrospectively registered, https://www.clinicaltrials.gov/ct2/show/NCT03634202","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42453291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信